Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the recipient of unusually large options trading on Friday. Stock investors acquired 12,356 call options on the stock. This is an increase of 446% compared to the average volume of 2,263 call options.

Capricor Therapeutics Trading Down 0.7%

Capricor Therapeutics stock opened at $19.70 on Friday. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -8.49 and a beta of 0.42. The company’s 50-day moving average price is $25.29 and its two-hundred day moving average price is $27.46.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Research analysts expect that Capricor Therapeutics will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

CAPR has been the topic of several analyst reports. LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Finally, Roth Capital restated a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

Insider Transactions at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 50,000 shares of company stock valued at $1,551,658 in the last quarter. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Walleye Capital LLC bought a new stake in shares of Capricor Therapeutics in the 1st quarter worth $5,397,000. Creek Drive Management Group LLC bought a new position in Capricor Therapeutics during the fourth quarter valued at about $1,039,000. Moody Aldrich Partners LLC bought a new position in Capricor Therapeutics during the fourth quarter valued at about $6,025,000. UBS Group AG grew its holdings in Capricor Therapeutics by 91.0% during the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock worth $6,875,000 after acquiring an additional 113,499 shares during the period. Finally, HBK Sorce Advisory LLC grew its holdings in Capricor Therapeutics by 19.4% during the fourth quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock worth $5,879,000 after acquiring an additional 33,128 shares during the period. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.